Cargando…

Liquid Biopsy: A Multi-Parametric Analysis of Mutation Status, Circulating Tumor Cells and Inflammatory Markers in EGFR-Mutated NSCLC

The liquid biopsy has the potential to improve patient care in the diagnostic and therapeutic setting in non-small cell lung cancer (NSCLC). Consented patients with epidermal growth factor receptor (EGFR) positive disease (n = 21) were stratified into two cohorts: those currently receiving EGFR tyro...

Descripción completa

Detalles Bibliográficos
Autores principales: Barr, Martin P., Baird, Anne-Marie, Halliday, Sophia, Martin, Petra, Allott, Emma H., Phelan, James, Korpanty, Greg, Coate, Linda, O’Brien, Cathal, Gray, Steven G., Sui, Jane S. Y., Hayes, Brian, Cuffe, Sinead, Finn, Stephen P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600124/
https://www.ncbi.nlm.nih.gov/pubmed/36292049
http://dx.doi.org/10.3390/diagnostics12102360
_version_ 1784816763347664896
author Barr, Martin P.
Baird, Anne-Marie
Halliday, Sophia
Martin, Petra
Allott, Emma H.
Phelan, James
Korpanty, Greg
Coate, Linda
O’Brien, Cathal
Gray, Steven G.
Sui, Jane S. Y.
Hayes, Brian
Cuffe, Sinead
Finn, Stephen P.
author_facet Barr, Martin P.
Baird, Anne-Marie
Halliday, Sophia
Martin, Petra
Allott, Emma H.
Phelan, James
Korpanty, Greg
Coate, Linda
O’Brien, Cathal
Gray, Steven G.
Sui, Jane S. Y.
Hayes, Brian
Cuffe, Sinead
Finn, Stephen P.
author_sort Barr, Martin P.
collection PubMed
description The liquid biopsy has the potential to improve patient care in the diagnostic and therapeutic setting in non-small cell lung cancer (NSCLC). Consented patients with epidermal growth factor receptor (EGFR) positive disease (n = 21) were stratified into two cohorts: those currently receiving EGFR tyrosine kinase inhibitor (TKI) therapy (n = 9) and newly diagnosed EGFR TKI treatment-naïve patients (n = 12). Plasma genotyping of cell-free DNA was carried out using the FDA-approved cobas(®) EGFR mutation test v2 and compared to next generation sequencing (NGS) cfDNA panels. Circulating tumor cell (CTC) numbers were correlated with treatment response and EGFR exon 20 p.T790M. The prognostic significance of the neutrophil to lymphocyte ratio (NLR) and lactate dehydrogenase (LDH) was also investigated. Patients in cohort 1 with an EGFR exon 20 p.T790M mutation progressed more rapidly than those with an EGFR sensitizing mutation, while patients in cohort 2 had a significantly longer progression-free survival (p = 0.04). EGFR exon 20 p.T790M was detected by liquid biopsy prior to disease progression indicated by computed tomography (CT) imaging. The cobas(®) EGFR mutation test detected a significantly greater number of exon 20 p.T790M mutations (p = 0.05). High NLR and derived neutrophil to lymphocyte ratio (dNLR) were associated with shorter time to progression and worse survival outcomes (p < 0.05). High LDH levels were significantly associated with shorter time to disease progression (p = 0.03). These data support the use of liquid biopsy for monitoring EGFR mutations and inflammatory markers as prognostic indicators in NSCLC.
format Online
Article
Text
id pubmed-9600124
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96001242022-10-27 Liquid Biopsy: A Multi-Parametric Analysis of Mutation Status, Circulating Tumor Cells and Inflammatory Markers in EGFR-Mutated NSCLC Barr, Martin P. Baird, Anne-Marie Halliday, Sophia Martin, Petra Allott, Emma H. Phelan, James Korpanty, Greg Coate, Linda O’Brien, Cathal Gray, Steven G. Sui, Jane S. Y. Hayes, Brian Cuffe, Sinead Finn, Stephen P. Diagnostics (Basel) Article The liquid biopsy has the potential to improve patient care in the diagnostic and therapeutic setting in non-small cell lung cancer (NSCLC). Consented patients with epidermal growth factor receptor (EGFR) positive disease (n = 21) were stratified into two cohorts: those currently receiving EGFR tyrosine kinase inhibitor (TKI) therapy (n = 9) and newly diagnosed EGFR TKI treatment-naïve patients (n = 12). Plasma genotyping of cell-free DNA was carried out using the FDA-approved cobas(®) EGFR mutation test v2 and compared to next generation sequencing (NGS) cfDNA panels. Circulating tumor cell (CTC) numbers were correlated with treatment response and EGFR exon 20 p.T790M. The prognostic significance of the neutrophil to lymphocyte ratio (NLR) and lactate dehydrogenase (LDH) was also investigated. Patients in cohort 1 with an EGFR exon 20 p.T790M mutation progressed more rapidly than those with an EGFR sensitizing mutation, while patients in cohort 2 had a significantly longer progression-free survival (p = 0.04). EGFR exon 20 p.T790M was detected by liquid biopsy prior to disease progression indicated by computed tomography (CT) imaging. The cobas(®) EGFR mutation test detected a significantly greater number of exon 20 p.T790M mutations (p = 0.05). High NLR and derived neutrophil to lymphocyte ratio (dNLR) were associated with shorter time to progression and worse survival outcomes (p < 0.05). High LDH levels were significantly associated with shorter time to disease progression (p = 0.03). These data support the use of liquid biopsy for monitoring EGFR mutations and inflammatory markers as prognostic indicators in NSCLC. MDPI 2022-09-29 /pmc/articles/PMC9600124/ /pubmed/36292049 http://dx.doi.org/10.3390/diagnostics12102360 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Barr, Martin P.
Baird, Anne-Marie
Halliday, Sophia
Martin, Petra
Allott, Emma H.
Phelan, James
Korpanty, Greg
Coate, Linda
O’Brien, Cathal
Gray, Steven G.
Sui, Jane S. Y.
Hayes, Brian
Cuffe, Sinead
Finn, Stephen P.
Liquid Biopsy: A Multi-Parametric Analysis of Mutation Status, Circulating Tumor Cells and Inflammatory Markers in EGFR-Mutated NSCLC
title Liquid Biopsy: A Multi-Parametric Analysis of Mutation Status, Circulating Tumor Cells and Inflammatory Markers in EGFR-Mutated NSCLC
title_full Liquid Biopsy: A Multi-Parametric Analysis of Mutation Status, Circulating Tumor Cells and Inflammatory Markers in EGFR-Mutated NSCLC
title_fullStr Liquid Biopsy: A Multi-Parametric Analysis of Mutation Status, Circulating Tumor Cells and Inflammatory Markers in EGFR-Mutated NSCLC
title_full_unstemmed Liquid Biopsy: A Multi-Parametric Analysis of Mutation Status, Circulating Tumor Cells and Inflammatory Markers in EGFR-Mutated NSCLC
title_short Liquid Biopsy: A Multi-Parametric Analysis of Mutation Status, Circulating Tumor Cells and Inflammatory Markers in EGFR-Mutated NSCLC
title_sort liquid biopsy: a multi-parametric analysis of mutation status, circulating tumor cells and inflammatory markers in egfr-mutated nsclc
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600124/
https://www.ncbi.nlm.nih.gov/pubmed/36292049
http://dx.doi.org/10.3390/diagnostics12102360
work_keys_str_mv AT barrmartinp liquidbiopsyamultiparametricanalysisofmutationstatuscirculatingtumorcellsandinflammatorymarkersinegfrmutatednsclc
AT bairdannemarie liquidbiopsyamultiparametricanalysisofmutationstatuscirculatingtumorcellsandinflammatorymarkersinegfrmutatednsclc
AT hallidaysophia liquidbiopsyamultiparametricanalysisofmutationstatuscirculatingtumorcellsandinflammatorymarkersinegfrmutatednsclc
AT martinpetra liquidbiopsyamultiparametricanalysisofmutationstatuscirculatingtumorcellsandinflammatorymarkersinegfrmutatednsclc
AT allottemmah liquidbiopsyamultiparametricanalysisofmutationstatuscirculatingtumorcellsandinflammatorymarkersinegfrmutatednsclc
AT phelanjames liquidbiopsyamultiparametricanalysisofmutationstatuscirculatingtumorcellsandinflammatorymarkersinegfrmutatednsclc
AT korpantygreg liquidbiopsyamultiparametricanalysisofmutationstatuscirculatingtumorcellsandinflammatorymarkersinegfrmutatednsclc
AT coatelinda liquidbiopsyamultiparametricanalysisofmutationstatuscirculatingtumorcellsandinflammatorymarkersinegfrmutatednsclc
AT obriencathal liquidbiopsyamultiparametricanalysisofmutationstatuscirculatingtumorcellsandinflammatorymarkersinegfrmutatednsclc
AT graysteveng liquidbiopsyamultiparametricanalysisofmutationstatuscirculatingtumorcellsandinflammatorymarkersinegfrmutatednsclc
AT suijanesy liquidbiopsyamultiparametricanalysisofmutationstatuscirculatingtumorcellsandinflammatorymarkersinegfrmutatednsclc
AT hayesbrian liquidbiopsyamultiparametricanalysisofmutationstatuscirculatingtumorcellsandinflammatorymarkersinegfrmutatednsclc
AT cuffesinead liquidbiopsyamultiparametricanalysisofmutationstatuscirculatingtumorcellsandinflammatorymarkersinegfrmutatednsclc
AT finnstephenp liquidbiopsyamultiparametricanalysisofmutationstatuscirculatingtumorcellsandinflammatorymarkersinegfrmutatednsclc